Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myeloma
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2016
Price : $35 *
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Janssen-Cilag
- 06 Dec 2016 Results of pooled analysis of two trials (NCT00416273 and NCT00416208) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 14 Jun 2015 Results of pooled analysis of MMY3012 and MMY3013 trials presented at the 20th Congress of the European Haematology Association.
- 02 Jun 2015 Results of pooled analysis of MMY3012 and MMY3013 trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.